Glatiramer acetate delayed conversion to multiple sclerosis in patients with clinically isolated syndrome

Paulseth, J. E. Rick
January 2010
ACP Journal Club;1/19/2010, Vol. 152 Issue 1, p9
Academic Journal
The article discusses a study conducted by professor G. Comi and colleagues to know whether glatiramer acetate delays conversion to clinically definite multiple sclerosis (MS) in patients with clinically isolated syndrome (CIS). A randomized placebo-controlled trial was conducted in 481 patients 18 to 45 years of age who had 1 unifocal neurologic event in the previous 90 days and it was found that Glatiramer acetate reduces risk for conversion to MS.


Related Articles

  • ECHO.  // Journal of Neurology, Neurosurgery & Psychiatry;Jan2005, Vol. 76 Issue 1, p127 

    The article reports that dronabinol reduces central pain in multiple sclerosis (MS). Patients with central neuropathic pain associated with multiple sclerosis (MS) should have better prospects of pain relief now that a randomised controlled trial in Denmark has shown that an oral synthetic...

  • Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis. Van den Elskamp, I. J.; Knol, D. L.; Vrenken, H.; Karas, G.; Meijerman, A.; Filippi, M.; Kappos, L.; Fazekas, F.; Wagner, K.; Pohl, C.; Sandbrink, R.; Polman, C. H.; Uitdehaag, B. M. J.; Barkhof, F. // Multiple Sclerosis (13524585);Jun2010, Vol. 16 Issue 6, p660 

    Magnetization transfer ratio (MTR) is a sensitive parameter to quantify the integrity of myelinated white matter in patients with multiple sclerosis. Lesional MTR decreases in the acute phase due to demyelination, and subsequently shows recovery depending on the degree of remyelination in the...

  • Trial shows no clear benefit from cannabis for patients with MS. Dyer, Owen // BMJ: British Medical Journal (International Edition);11/15/2003, Vol. 327 Issue 7424, p1128 

    Reports on a three year trial on the use of cannabis in the treatment of multiple sclerosis symptoms. Lack of a definitive finding in the study which was funded by the Medical Research Council; Treatment with oral capsules containing either whole cannabis extract or THC, the principal active...

  • Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Goodin, D. S.; Bates, D. // Multiple Sclerosis (13524585);Oct2009, Vol. 15 Issue 10, p1175 

    Multiple sclerosis is a chronic, demyelinating disorder of the central nervous system. It is characterised by progressive neurological disability, which is likely to occur as a result of permanent axonal damage. Such damage may be reflected by brain atrophy, which can be identified early in the...

  • A systematic review of oral methotrexate for multiple sclerosis. Gray, O. M.; McDonnell, G. V.; Forbes, R. B. // Multiple Sclerosis (13524585);Aug2006, Vol. 12 Issue 4, p507 

    Oral methotrexate is a potent immunosuppressant, which could have a beneficial effect on relapse rates and delay disease progression in multiple sclerosis (MS). We performed a systematic review of all randomized controlled trials of oral methotrexate for MS. Of the two randomized controlled...

  • Multidisciplinary fatigue management programme in multiple sclerosis: a randomized clinical trial. Kos, D.; Duportail, M.; d'Hooghe, M. B.; Nagels, G.; Kerckhofs, E. // Multiple Sclerosis (13524585);Sep2007, Vol. 13 Issue 8, p996 

    Objective To establish the efficacy of a multidisciplinary fatigue management programme (MFMP) in MS. Method Fifty-one subjects with MS were randomly allocated to group A, who only received the four weeks MFMP, or group B receiving a placebo intervention programme first and the MFMP after 6...

  • Mixed messages about Provigil for MS fatigue. Kraut, Rochelle // Inside MS;Feb/Mar2006, Vol. 24 Issue 1, p29 

    The article considers the therapeutic use of Progivil for individuals with multiple sclerosis (MS). Physicians began prescribing Progivil for MS fatigue. Since there were no serious side effects, it seemed safe to give it a try. However, a rigorous controlled trial, published in the April 2005...

  • Efficacy of an executive function intervention programme in MS: a placebo-controlled and pseudo-randomized trial. Fink, Frauke; Rischkau, Eva; Butt, Martina; Klein, Jan; Eling, Paul; Hildebrandt, Helmut // Multiple Sclerosis (13524585);Sep2010, Vol. 16 Issue 9, p1148 

    We evaluated a rehabilitation programme for executive deficits in multiple sclerosis patients by comparing outcome scores of a cognitive intervention group (CIG; n = 11) with those of a placebo group (n = 14) and an untreated group (n = 15). Executive functioning and verbal learning improved...

  • A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Vollmer, T.; Sorensen, P.; Selmaj, K.; Zipp, F.; Havrdova, E.; Cohen, J.; Sasson, N.; Gilgun-Sherki, Y.; Arnold, D. // Journal of Neurology;Apr2014, Vol. 261 Issue 4, p773 

    The phase III placebo-controlled BRAVO study assessed laquinimod effects in patients with relapsing-remitting MS (RRMS), and descriptively compared laquinimod with interferon beta (IFNβ)-1a (Avonex reference arm). RRMS patients age 18-55 years with Expanded Disability Status Scale (EDSS)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics